![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Mechanistic pharmacokinetics/pharmacodynamics modelling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen and alanine transaminase changes in chronic hepatitis B patients:
Phase 2b analysis to inform Phase 3 decision-making
|
|
|
EASL 2022 June 22-26 London
Youssef AS1, Ismail M2, Magee M1, Theodore D3, Paff M4, Elston R5, Nader A1
1Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Collegeville, PA, USA; 2Enhanced Pharmacodynamics LLC, Buffalo, NY, USA; 3Development Clinical Sciences Hepatology/GI, GlaxoSmithKline, Research Triangle, NC, USA; 4Development, GlaxoSmithKline, Collegeville, PA, USA 5Development, Clinical Sciences Hepatology/GI, GlaxoSmithKline, Stevenage, Hertfordshire, UK
![0725221](../images/072522/072522-6/0725221.gif)
![0725222](../images/072522/072522-6/0725222.gif)
![0725223](../images/072522/072522-6/0725223.gif)
![0725224](../images/072522/072522-6/0725224.gif)
![0725225](../images/072522/072522-6/0725225.gif)
![0725226](../images/072522/072522-6/0725226.gif)
![0725227](../images/072522/072522-6/0725227.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|